These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 27992095)
1. Faecal occult blood testing screening for colorectal cancer and 'missed' interval cancers: are we ignoring the elephant in the room? Results of a multicentre study. George AT; Aggarwal S; Dharmavaram S; Menon A; Dube M; Vogler M; Field A Colorectal Dis; 2017 May; 19(5):O108-O114. PubMed ID: 27992095 [TBL] [Abstract][Full Text] [Related]
2. Patterns of uptake in a biennial faecal occult blood test screening programme for colorectal cancer. Steele RJ; McClements PL; Libby G; Carey FA; Fraser CG Colorectal Dis; 2014 Jan; 16(1):28-32. PubMed ID: 24034143 [TBL] [Abstract][Full Text] [Related]
3. Early detection of colorectal cancer with faecal occult blood test screening. Paimela H; Malila N; Palva T; Hakulinen T; Vertio H; Järvinen H Br J Surg; 2010 Oct; 97(10):1567-71. PubMed ID: 20603855 [TBL] [Abstract][Full Text] [Related]
4. Screen-detected colorectal cancers show improved cancer-specific survival when compared with cancers diagnosed via the 2-week suspected colorectal cancer referral guidelines. Courtney ED; Chong D; Tighe R; Easterbrook JR; Stebbings WS; Hernon J Colorectal Dis; 2013 Feb; 15(2):177-82. PubMed ID: 22709315 [TBL] [Abstract][Full Text] [Related]
5. Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site. Steele RJ; McClements P; Watling C; Libby G; Weller D; Brewster DH; Black R; Carey FA; Fraser CG Gut; 2012 Apr; 61(4):576-81. PubMed ID: 21930729 [TBL] [Abstract][Full Text] [Related]
6. Comparison of screen-detected and interval colorectal cancers in the Bowel Cancer Screening Programme. Gill MD; Bramble MG; Rees CJ; Lee TJ; Bradburn DM; Mills SJ Br J Cancer; 2012 Jul; 107(3):417-21. PubMed ID: 22782347 [TBL] [Abstract][Full Text] [Related]
7. Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test. Heresbach D; Manfredi S; D'halluin PN; Bretagne JF; Branger B Eur J Gastroenterol Hepatol; 2006 Apr; 18(4):427-33. PubMed ID: 16538116 [TBL] [Abstract][Full Text] [Related]
8. Outcomes of faecal occult blood tests requested outside the UK National Bowel Cancer Screening Programme. McDonald R; Tomlins A; Smith S; Harmston C J Clin Pathol; 2013 Apr; 66(4):330-4. PubMed ID: 23288919 [TBL] [Abstract][Full Text] [Related]
9. Improved 5-year survival of patients with immunochemical faecal blood test-screen-detected colorectal cancer versus non-screening cancers in northern Italy. Parente F; Vailati C; Boemo C; Bonoldi E; Ardizzoia A; Ilardo A; Tortorella F; Cereda D; Cremaschini M; Moretti R Dig Liver Dis; 2015 Jan; 47(1):68-72. PubMed ID: 25306524 [TBL] [Abstract][Full Text] [Related]
10. Interval cancers in a guaiac-based colorectal cancer screening programme: Consequences on sensitivity. Blom J; Törnberg S J Med Screen; 2017 Sep; 24(3):146-152. PubMed ID: 28142309 [TBL] [Abstract][Full Text] [Related]
11. Patients with 'interval' colorectal cancers have worse outcomes compared with cancers in patients who decline the National Bowel Cancer Screening Programme - Results from a Multicentre Study. George AT; Field A Colorectal Dis; 2017 Jun; 19(6):590-591. PubMed ID: 28494513 [No Abstract] [Full Text] [Related]
12. Colorectal cancers detected through screening are associated with lower stages and improved survival. Lindebjerg J; Osler M; Bisgaard C Dan Med J; 2014 Jan; 61(1):A4758. PubMed ID: 24393588 [TBL] [Abstract][Full Text] [Related]
13. Outcomes and cost evaluation of the first two rounds of a colorectal cancer screening program based on immunochemical fecal occult blood test in northern Italy. Parente F; Boemo C; Ardizzoia A; Costa M; Carzaniga P; Ilardo A; Moretti R; Cremaschini M; Parente EM; Pirola ME Endoscopy; 2013; 45(1):27-34. PubMed ID: 23254404 [TBL] [Abstract][Full Text] [Related]
14. A comparison of tumour and host prognostic factors in screen-detected vs nonscreen-detected colorectal cancer: a contemporaneous study. Mansouri D; McMillan DC; McIlveen E; Crighton EM; Morrison DS; Horgan PG Colorectal Dis; 2016 Oct; 18(10):967-975. PubMed ID: 26859503 [TBL] [Abstract][Full Text] [Related]
15. The National Health Service Bowel Cancer Screening Program: the early years. Rees CJ; Bevan R Expert Rev Gastroenterol Hepatol; 2013 Jul; 7(5):421-37. PubMed ID: 23899282 [TBL] [Abstract][Full Text] [Related]
16. Faecal occult blood test-based screening programme with high compliance for colonoscopy has a strong clinical impact on colorectal cancer. Parente F; Marino B; DeVecchi N; Moretti R; ; Ucci G; Tricomi P; Armellino A; Redaelli L; Bargiggia S; Cristofori E; Masala E; Tortorella F; Gattinoni A; Odinolfi F; Pirola ME Br J Surg; 2009 May; 96(5):533-40. PubMed ID: 19358181 [TBL] [Abstract][Full Text] [Related]
17. Interval faecal occult blood testing in a colonoscopy based screening programme detects additional pathology. Bampton PA; Sandford JJ; Cole SR; Smith A; Morcom J; Cadd B; Young GP Gut; 2005 Jun; 54(6):803-6. PubMed ID: 15888788 [TBL] [Abstract][Full Text] [Related]
18. Occurrence and characteristics of faecal immunochemical screen-detected cancers vs non-screen-detected cancers: Results from a Flemish colorectal cancer screening programme. van de Veerdonk W; Hoeck S; Peeters M; Van Hal G; Francart J; De Brabander I United European Gastroenterol J; 2020 Mar; 8(2):185-194. PubMed ID: 32213071 [TBL] [Abstract][Full Text] [Related]
19. Tailored telephone counselling to increase participation of underusers in a population-based colorectal cancer-screening programme with faecal occult blood test: A randomized controlled trial. Denis B; Broc G; Sauleau EA; Gendre I; Gana K; Perrin P Rev Epidemiol Sante Publique; 2017 Feb; 65(1):17-28. PubMed ID: 28089385 [TBL] [Abstract][Full Text] [Related]
20. The Psychological Impact of a Colorectal Cancer Diagnosis Following a Negative Fecal Occult Blood Test Result. Miles A; McClements PL; Steele RJ; Redeker C; Sevdalis N; Wardle J Cancer Epidemiol Biomarkers Prev; 2015 Jul; 24(7):1032-8. PubMed ID: 25924826 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]